Search Results - "Luthi, J"

Refine Results
  1. 1
  2. 2

    Biomimetic, synthetic HDL nanostructures for lymphoma by Yang, Shuo, Damlano, Marina G., Zhang, Heng, Tripathy, Sushant, Luthi, Andrea J., Rink, Jonathan S., Ugolkov, Andrey V., Singh, Amareshwar T. K., Dave, Sandeep S., Gordon, Leo I., Thaxton, C. Shad

    “…New therapies that challenge existing paradigms are needed for the treatment of cancer. We report a nanoparticle-enabled therapeutic approach to B-cell…”
    Get full text
    Journal Article
  3. 3

    Biomimetic High Density Lipoprotein Nanoparticles For Nucleic Acid Delivery by McMahon, Kaylin M, Mutharasan, R. Kannan, Tripathy, Sushant, Veliceasa, Dorina, Bobeica, Mariana, Shumaker, Dale K, Luthi, Andrea J, Helfand, Brian T, Ardehali, Hossein, Mirkin, Chad A, Volpert, Olga, Thaxton, C. Shad

    Published in Nano letters (09-03-2011)
    “…We report a gold nanoparticle-templated high density lipoprotein (HDL AuNP) platform for gene therapy that combines lipid-based nucleic acid transfection…”
    Get full text
    Journal Article
  4. 4

    Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? by Rosenthal, A, Luthi, J, Belohlavek, M, Kortüm, K M, Mookadam, F, Mayo, A, Fonseca, R, Bergsagel, P L, Reeder, C B, Mikhael, J R, Stewart, A K

    Published in Blood cancer journal (New York) (01-01-2016)
    “…Carfilzomib (Cfz) has been associated with an ~5% incidence of unexplained and unpredictable cardiovascular toxicity in clinical trials. We therefore…”
    Get full text
    Journal Article
  5. 5

    Robust passive and active efflux of cellular cholesterol to a designer functional mimic of high density lipoprotein by Luthi, Andrea J., Lyssenko, Nicholas N., Quach, Duyen, McMahon, Kaylin M., Millar, John S., Vickers, Kasey C., Rader, Daniel J., Phillips, Michael C., Mirkin, Chad A., Thaxton, C.Shad

    Published in Journal of lipid research (01-05-2015)
    “…The ability of HDL to support macrophage cholesterol efflux is an integral part of its atheroprotective action. Augmenting this ability, especially when HDL…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Tailoring of Biomimetic High-Density Lipoprotein Nanostructures Changes Cholesterol Binding and Efflux by Luthi, Andrea J, Zhang, Heng, Kim, Dongwoo, Giljohann, David A, Mirkin, Chad A, Thaxton, C. Shad

    Published in ACS nano (24-01-2012)
    “…Gold nanoparticles (Au NPs) were employed as templates to synthesize spherical, high-density lipoprotein (HDL) biomimics (HDL Au NPs) of different sizes and…”
    Get full text
    Journal Article
  8. 8

    Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07) by Zaman, K., Thürlimann, B., Huober, J., Schönenberger, A., Pagani, O., Lüthi, J., Simcock, M., Giobbie-Hurder, A., Berthod, G., Genton, C., Brauchli, P., Aebi, S.

    Published in Annals of oncology (01-06-2012)
    “…The risk of osteoporosis and fracture influences the selection of adjuvant endocrine therapy. We analyzed bone mineral density (BMD) in Swiss patients of the…”
    Get full text
    Journal Article
  9. 9

    Structural changes in skeletal muscle tissue with heavy-resistance exercise by Lüthi, J M, Howald, H, Claassen, H, Rösler, K, Vock, P, Hoppeler, H

    Published in International journal of sports medicine (01-06-1986)
    “…Muscle strength, muscle cross-sectional area, fiber size, fiber type distribution, capillarity, and mitochondrial volume were estimated before and after 6…”
    Get more information
    Journal Article
  10. 10

    Nanotechnology for synthetic high-density lipoproteins by Luthi, Andrea J, Patel, Pinal C, Ko, Caroline H, Mutharasan, R. Kannan, Mirkin, Chad A, Thaxton, C. Shad

    Published in Trends in molecular medicine (01-12-2010)
    “…Atherosclerosis is the disease mechanism responsible for coronary heart disease (CHD), the leading cause of death worldwide. One strategy to combat…”
    Get full text
    Journal Article
  11. 11

    Interval matrices for the bottleneck analysis of queueing network models with histogram-based parameters by Luthi, J.

    “…Bottleneck analysis using queueing network models is an important technique for the performance analysis and capacity planning of computer and communication…”
    Get full text
    Conference Proceeding
  12. 12

    Antibiotic use: is appropriateness expensive? by von Gunten, V, Reymond, J.-P, Boubaker, K, Gerstel, E, Eckert, P, Lüthi, J.-C, Troillet, N

    Published in The Journal of hospital infection (01-02-2009)
    “…Summary Antibiotics are prone to misuse. In this study, 37% of 600 antibiotic prescriptions in three hospitals were considered unnecessary. When antibiotic…”
    Get full text
    Journal Article
  13. 13

    Impact of an interdisciplinary strategy on antibiotic use: a prospective controlled study in three hospitals by von Gunten, V., Troillet, N., Beney, J., Boubaker, K., Lüthi, J.-C., Taffé, P., Reymond, J.-P.

    Published in Journal of antimicrobial chemotherapy (01-03-2005)
    “…Objectives: Evaluation of the impact of the implementation of practice guidelines, with or without their reinforcement by a pharmacist, on the intra-hospital…”
    Get full text
    Journal Article
  14. 14

    Redimune® NF Liquid, a ready-to-use, high-concentration intravenous immunoglobulin therapy preparation, is safe and typically well tolerated in the routine clinical management of a broad range of conditions by Piguet, D, Tosi, C, Lüthi, J.-M, Andresen, I, Juge, O

    Published in Clinical and experimental immunology (01-04-2008)
    “…In clinical practice, intravenous immunoglobulin therapy (IVIG) is used in the management of a wide variety of medical conditions. Observational studies…”
    Get full text
    Journal Article
  15. 15

    Readmissions and the quality of care in patients hospitalized with heart failure by Luthi, Jean-Christophe, Lund, Mary Jo, Sampietro-Colom, Laura, Kleinbaum, David G., Ballard, David J., McClellan, William M.

    “…Objectives. Clinical practice guidelines based on the results of randomized clinical trials recommend that patients with heart failure due to left ventricular…”
    Get full text
    Journal Article
  16. 16

    Studying sensitivities of an EJB performance model by Llado, C.M., Luthi, J.

    “…Often, at the time when a performance model is built, some of its input parameters are not known exactly. This can be for a variety of reasons, such as the…”
    Get full text
    Conference Proceeding
  17. 17

    Bias in parallel and distributed simulation systems by Kiesling, T., Khayari, R.E.A., Luthi, J.

    “…Even after several decades of research, modeling is considered an art, with a high liability to produce incorrect abstractions of real world systems…”
    Get full text
    Conference Proceeding
  18. 18

    Outcomes and the quality of care for patients hospitalized with heart failure by Luthi, Jean-Christophe, Flanders, W. Dana, Pitts, Stephen R., Burnand, Bernard, McClellan, William M.

    “…Objective. The purpose of this study was to determine whether process quality indicators derived from evidence-based guidelines for heart failure patients were…”
    Get full text
    Journal Article
  19. 19

    Performance bounds for distributed systems with workload variabilities and uncertainties by Lüthi, J., Majumdar, S., Kotsis, G., Haring, G.

    Published in Parallel computing (28-02-1997)
    “…Bounding techniques for queuing network models used to analyze the performance of parallel and distributed computer systems accept single values as model…”
    Get full text
    Journal Article
  20. 20